Trial NCT02636582

Nelipepimut-S Plus GM-CSF Vaccine Therapy in Treating Patients With Breast Cancer

This phase II trial studies how well nelipepimut-S plus GM-CSF vaccine therapy or
sargramostim works in treating patients with breast cancer. Vaccines made from peptide or
antigen and/or a person's white blood cells mixed with tumor proteins may help the body build
an effective immune response to kill tumor cells that express breast cancer. It is not yet
known whether nelipepimut-S plus GM-CSF vaccine or sargramostim is more effective in treating
patients with breast cancer.

Intervention

Laboratory Biomarker Analysis, Nelipepimut-S Plus GM-CSF Vaccine, Sargramostim, Surgical Procedure

Condition

Breast Ductal Carcinoma In Situ

Investigators

Elizabeth A Mittendorf

See list of participating sites